Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Payables: 2010-2025

Historic Payables for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to $6.1 million.

  • Sunshine Biopharma's Payables rose 47.63% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 40.65%. This contributed to the annual value of $5.5 million for FY2024, which is 114.39% up from last year.
  • As of Q3 2025, Sunshine Biopharma's Payables stood at $6.1 million, which was up 27.93% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Payables registered a high of $6.1 million during Q3 2025, and its lowest value of $95,234 during Q1 2022.
  • Moreover, its 3-year median value for Payables was $4.2 million (2024), whereas its average is $4.0 million.
  • In the last 5 years, Sunshine Biopharma's Payables plummeted by 85.78% in 2022 and then soared by 2,773.09% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Payables stood at $1.9 million in 2021, then soared by 44.26% to $2.8 million in 2022, then declined by 7.75% to $2.6 million in 2023, then spiked by 114.39% to $5.5 million in 2024, then surged by 47.63% to $6.1 million in 2025.
  • Its Payables stands at $6.1 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.0 million for Q1 2025.